Patents Assigned to Reponex Pharmaceuticals Aps
  • Method of alleviating chronic wounds
    Patent number: 11813309
    Abstract: The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), sucrose octasulfate or sucralfate and hyaluronic acid for the treatment, pre-emptive treatment or prophylaxis of ulcers, wounds and other injuries to the skin or membranes of the body. Other aspects of the invention are methods of treatment or prevention using the compositions described, as well as an application device for use in the methods provided.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: November 14, 2023
    Assignee: Reponex Pharmaceuticals APS
    Inventor: Lars Heslet
  • Methods and Compositions for Enhancing Pulmonary Host Defense in Acute and Chronic Radiation Syndrome, Therapeutic Radiation Intervention and Cancer Therapy
    Publication number: 20180078614
    Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 22, 2018
    Applicant: REPONEX PHARMACEUTICALS APS
    Inventor: Lars Heslet
  • Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
    Patent number: 9855316
    Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: January 2, 2018
    Assignee: REPONEX PHARMACEUTICALS APS
    Inventor: Lars Heslet
  • COMPOSITIONS FOR TREATING LUNG INFECTIONS BY AIRWAY ADMINISTRATION
    Publication number: 20170035850
    Abstract: The present invention provides compositions comprising as an essential feature granulocyte-macrophage colony-stimulating factor (GM-CSF) together with fosfomycin for the treatment of bacterial lung infections by administration via the airways.
    Type: Application
    Filed: March 6, 2015
    Publication date: February 9, 2017
    Applicant: Reponex Pharmaceuticals ApS
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • GM-CSF FOR TREATMENT OF CHRONIC ORAL MUCOSITIS
    Publication number: 20160000875
    Abstract: The present invention relates to compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), or homologues thereof, and its use for treatment, prevention or alleviation of oral mucositis. The composition is preferably an aqueous solution forlocaloral administration.
    Type: Application
    Filed: February 19, 2014
    Publication date: January 7, 2016
    Applicant: Reponex Pharmaceuticals ApS
    Inventor: Lars Heslet
  • GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF BRONCHIAL ASTHMA
    Publication number: 20150174204
    Abstract: The present invention relates to granulocyte-macrophage colony-stimulating factor (GM-CSF) for use in the treatment of bronchial asthma by administering via the airway an effective amount of GM-CSF or a functional homologue thereof. The invention further relates to a method for treating bronchial asthma comprising the administration of GM-CSF to a patient in need thereof, in particular moderate and severe forms of bronchial asthma.
    Type: Application
    Filed: July 19, 2013
    Publication date: June 25, 2015
    Applicant: Reponex Pharmaceuticals Aps
    Inventor: Lars Heslet